<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881308</url>
  </required_header>
  <id_info>
    <org_study_id>DIA2012-1/ver3_1</org_study_id>
    <secondary_id>2012-005275-14</secondary_id>
    <nct_id>NCT01881308</nct_id>
  </id_info>
  <brief_title>Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis</brief_title>
  <acronym>ARCTIC REWIND</acronym>
  <official_title>REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of disease-modifying anti-rheumatic drugs
      (DMARDs) dose reduction in patients with rheumatoid arthritis (RA).

      Remission is the treatment target in RA, but knowledge about the best way to treat RA
      patients who achieve sustained remission is limited. DMARDs have potential serious adverse
      events, and biologic DMARDs are costly to the society. The objectives for ARCTIC REWIND are
      to assess the effect of tapering and withdrawal of DMARDs on disease activity in RA patients
      in sustained remission, to study predictors for successful tapering and withdrawal of DMARDs
      in this patient group, and to study cost-effectiveness of different treatment options in RA
      remission.

      ARCTIC REWIND is a randomized, open, controlled, parallel-group, multicenter, phase IV,
      non-inferiority strategy study. Patients with less than five years of disease duration and
      stable remission for at least 12 months are randomized to either continued stable treatment
      or tapering and withdrawal of DMARDs, including tumor necrosis factor (TNF) inhibitors and
      synthetic DMARDs. Patients are assessed by clinical examination, patient reported outcome
      measures, ultrasonography, MRI and X-ray, and monitored for adverse events. The primary
      endpoint of the study is the proportion of patients who are non-failures (have not
      experienced a flare) at 12 months. Secondary endpoints include composite disease activity
      scores and remission criteria, joint damage and inflammation assessed by various imaging
      modalities, work participation, health care resource use and health related quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who are non-failures (have not experienced a flare)</measure>
    <time_frame>12 months</time_frame>
    <description>Flare is defined as composite measure: (1) An increase in disease activity score (DAS) to &gt;1.6 AND (2) a change in DAS of at least 0.6 AND (3) &gt; 1 swollen joint. If a patient does not fulfill this formal definition, but experiences a clinically significant flare according to the investigator and patient, this is treated as a flare.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Stable dose TNF inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stepdown and withdrawal of TNF inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable dose synthetic DMARD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable dose of synthetic DMARDs, either monotherapy or combination therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synthetic DMARD dose reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARCTIC follow-up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are treated according to the ARCTIC treatment schedule based on disease activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF inhibitors</intervention_name>
    <arm_group_label>Stable dose TNF inhibitor</arm_group_label>
    <arm_group_label>Stepdown and withdrawal of TNF inhibitor</arm_group_label>
    <arm_group_label>ARCTIC follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synthetic DMARD(s)</intervention_name>
    <arm_group_label>Stable dose synthetic DMARD</arm_group_label>
    <arm_group_label>Synthetic DMARD dose reduction</arm_group_label>
    <arm_group_label>ARCTIC follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-medication: Synthetic DMARDs</intervention_name>
    <description>Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.</description>
    <arm_group_label>Stable dose TNF inhibitor</arm_group_label>
    <arm_group_label>Stepdown and withdrawal of TNF inhibitor</arm_group_label>
    <arm_group_label>ARCTIC follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis according to the 2010 American College of Rheumatology
             (ACR)/European League Against Rheumatism (EULAR) classification criteria

          -  Male or non-pregnant, non-nursing female

          -  &gt;18 years of age and &lt;80 years of age

          -  Disease duration less than five years at inclusion into ARCTIC REWIND, defined as time
             from first joint swelling

          -  Sustained remission for ≥12 months according to DAS or Disease Activity Score based on
             28 joints (DAS28), with documented remission status at a minimum of 2 consecutive
             visits during the last 18 months OR participation in the first ARCTIC trial

          -  DAS &lt;1.6 and no swollen joints at inclusion OR participation in the first ARCTIC trial

          -  Unchanged treatment with TNF inhibitors and/or synthetic DMARDs during the previous 12
             months, with a stable or reduced dose of glucocorticosteroids OR participation in the
             first ARCTIC trial

          -  Subject capable of understanding and signing an informed consent form

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Abnormal renal function, defined as serum creatinine &gt;142 μmol/L in female and &gt;168
             μmol/L in male, or a glomerular filtration rate (GFR) &lt;40 mL/min/1.73 m2

          -  Abnormal liver function (defined as aspartate transaminase (ASAT)/alanine
             aminotransferase (ALAT) &gt;3x upper normal limit), active or recent hepatitis, cirrhosis

          -  Major co-morbidities, such as severe malignancies, severe diabetic mellitus, severe
             infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3
             or 4) and/or severe respiratory diseases

          -  Leukopenia and/or thrombocytopenia

          -  Inadequate birth control, pregnancy, and/or breastfeeding

          -  Indications of active tuberculosis

          -  Psychiatric or mental disorders, alcohol abuse or other substance abuse, language
             barriers or other factors which makes adherence to the study protocol impossible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Espen A. Haavardsholm, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tore K Kvien, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siri Lillegraven, MD MPH</last_name>
    <phone>+4793467767</phone>
    <email>siri.lillegraven@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Espen A. Haavardsholm, MD PhD</last_name>
    <phone>+4722451500</phone>
    <email>e.a.haavardsholm@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Rheumatology, Haukeland University Hospital, Helse Bergen HF</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tor Magne Madland, MD PhD</last_name>
      <phone>+47 55 97 54 00</phone>
      <email>tor.madland@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Tor Magne Madland, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Drammen Hospital, Vestre Viken HF</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Åse S. Lexberg, MD</last_name>
      <phone>+4732803000</phone>
      <email>Ase.Stavland.Lexberg@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Åse S Lexberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Sykehuset Østfold HF</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1603</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Høili, MD</last_name>
      <phone>+4769866400</phone>
      <email>chrhoi@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Christian Høili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haugesunds Sanitetsforening Revmatismesykehus</name>
      <address>
        <city>Haugesund</city>
        <zip>5504</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Stray, MD</last_name>
      <email>hilde.stray@hsr.as</email>
    </contact>
    <investigator>
      <last_name>Hilde Stray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Sørlandet Sykehus HF</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dag Soldal, MD</last_name>
      <phone>+4738073000</phone>
      <email>Dag.Magnar.Soldal@sshf.no</email>
    </contact>
    <investigator>
      <last_name>Dag Soldal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revmatolog Anne Noraas Bendvold</name>
      <address>
        <city>Kristiansand</city>
        <zip>4611</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne N. Bendvold, MD</last_name>
      <email>anne.noraas.bendvold@revmatologene.nhn.no</email>
    </contact>
    <investigator>
      <last_name>Anne N. Bendvold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revmatismesykehuset AS</name>
      <address>
        <city>Lillehammer</city>
        <zip>2609</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Spada, MD</last_name>
      <phone>+4761279500</phone>
      <email>Cristina.Spada@revmatismesykehuset.no</email>
    </contact>
    <investigator>
      <last_name>Cristina Spada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0319</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Birgitte Aga, MD</last_name>
      <phone>+22451500</phone>
      <email>anna.birgitte.aga@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna-Birgitte Aga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martina Hansens Hospital AS</name>
      <address>
        <city>Sandvika</city>
        <zip>1306</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Haukeland, MD</last_name>
      <phone>+4767809400</phone>
      <email>hildehaukeland@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hilde Haukeland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge HF</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnstein Bakland, MD PhD</last_name>
      <phone>+4777627261</phone>
      <email>Gunnstein.Bakland@unn.no</email>
    </contact>
    <investigator>
      <last_name>Gunnstein Bakland, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, St Olavs Hospital HF</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erik Rødevand, MD</last_name>
      <phone>+4772826400</phone>
      <email>Erik.Rodevand@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Erik Rødevand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Helse Møre og Romsdal HF</name>
      <address>
        <city>Ålesund</city>
        <zip>6026</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hallvard Fremstad, MD</last_name>
      <phone>+4770105400</phone>
      <email>hallvard.fremstad@helse-sunnmore.no</email>
    </contact>
    <investigator>
      <last_name>Hallvard Fremstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Espen A. Haavardsholm, MD PhD</investigator_full_name>
    <investigator_title>MD PhD, Postdoc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

